Therefore, the primary aim of this study was to assess the prognostic value of several promising emerging cardiac, neurohormonal, renal and inflammatory biomarkers beyond that provided by NT‐proBNP, troponin, and hsTnT individually and in combination, in patients enrolled in the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED‐HF) trial. The gene discussed is NPPB; the disease is heart failure.